Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With<i>EGFR</i>-Mutated Advanced Non–Small Cell Lung CancerPedro Nazareth Aguiar, Gilberto Lopes, Pui San Tan et al.|JAMA Oncology|2018Cited by 125
Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancerPedro Nazareth Aguiar, Gilberto Lopes, Pui San Tan et al.|Einstein (São Paulo)|2019Cited by 19
Network metanalysis and cost-effectiveness of abiraterone, docetaxel or placebo plus androgen deprivation therapy (ADT) for hormone-sensitive advanced prostate cancer.Pedro Nazareth Aguiar, Gilberto Lopes, Pui San Tan et al.|Journal of Clinical Oncology|2018Cited by 7